Holen Sie sich die Stockscreener-App
26.82
7.10%
-2.05
Schlusskurs vom Vortag:
$28.87
Offen:
$28.68
24-Stunden-Volumen:
18.97M
Relative Volume:
0.66
Marktkapitalisierung:
$6.21B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$128.37M
KGV:
51.37
EPS:
0.5221
Netto-Cashflow:
$57.42M
1W Leistung:
+2.41%
1M Leistung:
+7.15%
6M Leistung:
-27.92%
1J Leistung:
-53.07%
1-Tages-Spanne:
$26.52
$28.78
1-Wochen-Bereich:
$25.96
$29.75
52-Wochen-Spanne:
$13.74
$70.43
Hims Hers Health Inc Stock (HIMS) Company Profile
Firmenname
Hims Hers Health Inc
Sektor
Telefon
415-851-0195
Adresse
2269 CHESTNUT ST, SAN FRANCISCO
Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HIMS
Hims Hers Health Inc
|
26.82 | 6.21B | 2.35B | 128.37M | 57.42M | 0.5221 |
TAK
Takeda Pharmaceutical Co Adr
|
15.91 | 50.27B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 40.32B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.13 | 40.31B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.57 | 33.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
545.96 | 23.17B | 3.17B | 1.29B | 1.01B | 27.09 |
Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Eingeleitet | JP Morgan | Overweight |
| 2026-03-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2026-03-10 | Hochstufung | Citigroup | Sell → Neutral |
| 2026-03-09 | Hochstufung | Needham | Hold → Buy |
| 2026-02-24 | Herabstufung | BTIG Research | Buy → Neutral |
| 2026-01-12 | Eingeleitet | Evercore ISI | In-line |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-21 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2025-06-23 | Herabstufung | Needham | Buy → Hold |
| 2025-06-04 | Bestätigt | Needham | Buy |
| 2025-04-29 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-01-10 | Herabstufung | Citigroup | Neutral → Sell |
| 2025-01-07 | Eingeleitet | BTIG Research | Buy |
| 2024-12-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-11-14 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-08-22 | Eingeleitet | Needham | Buy |
| 2024-08-09 | Herabstufung | Imperial Capital | Outperform → In-line |
| 2024-05-22 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-04-16 | Herabstufung | Jefferies | Buy → Hold |
| 2024-04-10 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-02-28 | Hochstufung | Imperial Capital | In-line → Outperform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | Imperial Capital | In-line |
| 2023-07-28 | Eingeleitet | TD Cowen | Outperform |
| 2023-04-11 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-02-09 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-08 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-11-08 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-10-17 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-07-15 | Eingeleitet | SVB Leerink | Underperform |
| 2022-04-14 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Outperform |
| 2022-03-10 | Eingeleitet | Deutsche Bank | Hold |
| 2021-12-02 | Eingeleitet | Jefferies | Hold |
| 2021-11-11 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-07-06 | Eingeleitet | BofA Securities | Neutral |
| 2021-05-20 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2021-04-21 | Eingeleitet | Truist | Hold |
| 2021-03-09 | Eingeleitet | Credit Suisse | Neutral |
| 2021-03-02 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Eingeleitet | Citigroup | Neutral |
| 2021-02-12 | Eingeleitet | Piper Sandler | Neutral |
| 2021-02-08 | Eingeleitet | Tigress Financial | Buy |
Alle ansehen
Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten
Hims & Hers Fell 7% and Wall Street’s Price Target Now Sits Below the Stock - TIKR.com
A Look at Hims & Hers Health Inc (HIMS) After 7.1% Decline -- GF Value $38.10 vs Price $26.82 - GuruFocus
Hims & Hers at The Economist's Inaugural Economics of Obesity and Metabolic Health Summit - Hims & Hers Newsroom
Hims & Hers Health Stock Slides Friday: What's Going On? - Benzinga
Hims & Hers Health, Inc. (HIMS) stock drops despite market gains: Important facts to note - MSN
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat - Stocktwits
Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance
Hims & Hers Health (HIMS) up 15.8% since last earnings report: Can it continue? - MSN
OMCL vs. HIMS: Which Stock Is the Better Value Option? - Yahoo Finance
Hims & Hers Health (HIMS) Up 15.8% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Hims & Hers Health (NYSE:HIMS) Downgraded to "Strong Sell" Rating by Zacks Research - MarketBeat
Investor relations - HIMS Investor Relations
Hims & Hers (HIMS) Stock: Investors Reassess Growth Path in Digital Health Weight-Loss Push - parameter.io
Hims & Hers Health, Inc. (HIMS) Investigation: Bronstein, Gewirtz - The National Law Review
Why Hims & Hers Stock Jumped Today as Its Weight-Loss Bet Gets a Second Look - TechStock²
Hims & Hers Health Jumps 5.0% Amid Sector-Wide Rally - AlphaStreet
Hims & Hers Stock Edges Higher: What's Going On? - Benzinga
Truist Financial Maintains Hims & Hers Health(HIMS.US) With Hold Rating - Moomoo
X Square Capital LLC Raises Stake in Hims & Hers Health, Inc. $HIMS - MarketBeat
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.7% Rally? GF Value Says Undervalued - GuruFocus
Is It Too Late to Buy Hims & Hers Health Inc (HIMS) After 3.7% R - GuruFocus
HIMS Stock Slips Despite Early Eucalyptus Buyout Close: Analyst Sees 10% Downside On GLP-1 Profit Risks - Stocktwits
Hims & Hers Health Inc (HIMS) Stock Price, Trades & News - GuruFocus
Investors heavily search Hims & Hers Health, Inc. (HIMS): Here is what you need to know - MSN
HIMS Stock Eyes 2-Week Green Streak: Analyst Sees Nearly 20% Upside On Multi-Year Opportunity In Peptides - Stocktwits
Investors Heavily Search Hims & Hers Health, Inc. (HIMS): Here is What You Need to Know - Yahoo Finance
Hims & Hers Health, Inc. $HIMS Shares Sold by Capital World Investors - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Buys 43,826 Shares of Hims & Hers Health, Inc. $HIMS - MarketBeat
HIMS News | HIMS & HERS HEALTH INC (NYSE:HIMS) - ChartMill
Bronstein, Gewirtz & Grossman, LLC Is Investigating Hims & Hers H - The National Law Review
PPI Report April 2026: How Inflation Data Is Moving HIMS, CEG, and PLUG Stock Today - TradingKey
Hims & Hers Health Stock (HIMS) Opinions on Biotech Sector Momentum - Quiver Quantitative
Is Hims & Hers Health, Inc. (HIMS) A Good Stock To Buy Now? - Insider Monkey
HIMS vs. TEM: Which AI healthcare stock offers better upside now? - MSN
1,914,177 Shares in Hims & Hers Health, Inc. $HIMS Bought by Norges Bank - MarketBeat
Hims & Hers Health Options Spot-On: On June 1st, 185.47K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
Hims & Hers Health, Inc. Class A Trade Ideas — XETR:82W - TradingView
Hims & Hers Health Options Spot-On: On June 3rd, 96,548 Contracts Were Traded, With 1.06 Million Open Interest - Moomoo
How Investors Are Reacting To Hims & Hers Health (HIMS) Hiring a Longevity-Focused Chief Medical Officer - simplywall.st
HIMS Stock On The Mend? New Testosterone Push Builds As GLP-1 Gold Rush Gets Crowded - Stocktwits
Hims & Hers Health Options Spot-On: On June 5th, 153.61K Contracts Were Traded, With 1.08 Million Open Interest - Moomoo
Hims CMO Appointment Highlights Longevity Focus And Raises Valuation Questions - Yahoo Finance
Hims & Hers Stock Closes Eucalyptus Deal With a $20 Billion Peptide Bet on Deck. Here’s What to Expect - TIKR.com
Hims & Hers expands UK footprint with Eucalyptus acquisition - Pharmacy Business
What is behind Hims & Hers Health stock's recent drop in value today - Traders Union
Great News: Wall Street Is Turning Bullish on This Troubled Telehealth Stock - The Globe and Mail
Hims & Hers Health stock price forecast: $34.06 resistance as HIMS climbs 1.82% - Traders Union
HIMS Stock Eyes Breakout Week: Eight New Partners Fuel Push To Build An All-In-One Health Platform - Stocktwits
HIMS Stock | Hims & Hers Health, Inc. Price, Quote, News & Analysis - TipRanks
Hims & Hers Health Jumps 7.0% Amid Sector-Wide Rally - AlphaStreet
Hims & Hers Names Dr. Anant Vinjamoori as Chief Medical Officer of Hims - Hims & Hers Newsroom
Finanzdaten der Hims Hers Health Inc-Aktie (HIMS)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.37%
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):